LadRx is a biopharmaceutical company focused on discovering and developing new therapeutics to treat patients with high unmet needs.
LadRx has a milestone and royalty agreement with Orphazyme A/S (Nasdaq - "ORPH") for arimoclomol. Arimoclomol was recently sold to KemPharm, subject to approval on June 1, 2022. The agreement can provide LadRx with potential milestones plus royalties paid on arimoclomol. Orphazyme is currently...
LadRx is a biopharmaceutical company focused on discovering and developing new therapeutics to treat patients with high unmet needs.
LadRx has a milestone and royalty agreement with Orphazyme A/S (Nasdaq - "ORPH") for arimoclomol. Arimoclomol was recently sold to KemPharm, subject to approval on June 1, 2022. The agreement can provide LadRx with potential milestones plus royalties paid on arimoclomol. Orphazyme is currently studying arimoclomol in clinical trials for Nieman-Pick disease Type C (NPC) and Gaucher disease
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.